Laboratorio di Cardiologia Vascolare e Cardiologia Molecolare

Laboratorio di Cardiologia Vascolare e Cardiologia Molecolare

CENTRO DI RICERCHE DELLE MALATTIE CARDIOVASCOLARI
Prof. Ciro Indolfi

Collaborazioni:

  • Prof. Daniele Torella
  • Prof. Antonio Curcio
  • Prof. Giovanni Cuda
  • Dr. Howard Rockman
  • Prof. Enrico Vittorio Avvedimento
  • Prof. Alessandro Weisz
  • Dott. Chiara Mignona
  • Dott. Gianluca De Masi

Aree di ricerca: Stenosi, Ristenosi Arteriosa e Micro-RNAs

  • Il ruolo dei microRNA e dei non-coding RNA nella formazione di neointima in seguito ad angioplastica coronarica;
  • Identificazione e validazione di microRNA circolanti quali biomarcatori nelle Sindromi Coronariche Acute e nella trombosi coronarica;
  • Identificazione e validazione di nuovi Long Noncoding per la diagnosi precoce di Infarto Miocardico Acuto;
  • Identificazione di marcatori del rischio di Infarto Miocardico Acuto in giovane età mediante l’uso di metodiche di proteomica ed epigenomica;
  • Identificazione di biomarcatori per la gestione del paziente con Stenosi Aortica Severa mediante l’uso di metodiche di proteomica ed epigenomica.

Letteratura specifica

  1. MicroRNAs as Diagnostic and Prognostic Biomarkers in Ischemic Stroke-A Comprehensive Review and Bioinformatic Analysis. Eyileten C, Wicik Z, De Rosa S, Mirowska-Guzel D, Soplinska A, Indolfi C, Jastrzebska-Kurkowska I, Czlonkowska A, Postula M. Cells. 2018 Dec 6;7(12). pii: E249. doi: 10.3390/cells7120249. Review.
  2.  Non-coding RNAs in vascular remodeling and restenosis. Indolfi C, Iaconetti C, Gareri C, Polimeni A, De Rosa S. Vascul Pharmacol. 2018 Oct 24. pii: S1537-1891(18)30105-8. doi: 10.1016/j.vph.2018.10.006. [Epub ahead of print] Review.
  3. miRNA Regulation of the Hyperproliferative Phenotype of Vascular Smooth Muscle Cells in Diabetes. Torella D, Iaconetti C, Tarallo R, Marino F, Giurato G, Veneziano C, Aquila I, Scalise M, Mancuso T, Cianflone E, Valeriano C, Marotta P, Tammè L, Vicinanza C, Sasso FC, Cozzolino D, Torella M, Weisz A, Indolfi C. Diabetes. 2018 Dec;67(12):2554-2568. doi: 10.2337/db17-1434. Epub 2018 Sep 26.
  4. Diagnostic value of cardiac magnetic resonance and fluorodeoxyglucose-positron emission tomography for cardiac sarcoidosis with previous myocardial infarction: A case report. Yasuda M, Iwanaga Y, Kawamura T, Nakamura T, De Rosa S, Indolfi C, Miyazaki S.Medicine (Baltimore). 2018 Aug;97(35):e11938. doi: 10.1097/MD.0000000000011938.
  5. The Potential Role of Platelet-Related microRNAs in the Development of Cardiovascular Events in High-Risk Populations, Including Diabetic Patients: A Review. Pordzik J, Pisarz K, De Rosa S, Jones AD, Eyileten C, Indolfi C, Malek L, Postula M. Front Endocrinol (Lausanne). 2018 Mar 20;9:74. doi: 10.3389/fendo.2018.00074. eCollection 2018. Review.
  6. Hindlimb Ischemia Impairs Endothelial Recovery and Increases Neointimal Proliferation in the Carotid Artery. Sorrentino S, Iaconetti C, De Rosa S, Polimeni A, Sabatino J, Gareri C, Passafaro F, Mancuso T, Tammè L, Mignogna C, Camastra C, Esposito G, Curcio A, Torella D, Indolfi C. Sci Rep. 2018 Jan 15;8(1):761. doi: 10.1038/s41598-017-19136-6
  7. Diagnostic Performance of the Instantaneous Wave-Free Ratio: Comparison With Fractional Transcoronary concentration gradients of circulating microRNAs in heart failure. De Rosa S, Eposito F, Carella C, Strangio A, Ammirati G, Sabatino J, Abbate FG, Iaconetti C, Liguori V, Pergola V, Polimeni A, Coletta S, Gareri C, Trimarco B, Stabile G, Curcio A, Indolfi C, Rapacciuolo A. Eur J Heart Fail. 2018 Jun;20(6):1000-1010. doi: 10.1002/ejhf.1119. Epub 2018 Jan 4.
  8. Incidence, Clinical Presentation, and Predictors of Clinical Restenosis in Coronary Bioresorbable Scaffolds. Polimeni A, Weissner M, Schochlow K, Ullrich H, Indolfi C, Dijkstra J, Anadol R, Münzel T, Gori T. JACC Cardiovasc Interv. 2017 Sep 25;10(18):1819-1827. doi: 10.1016/j.jcin.2017.07.034.
  9. miR-125a-5p Modulates Phenotypic Switch of Vascular Smooth Muscle Cells by Targeting ETS-1. Gareri C, Iaconetti C, Sorrentino S, Covello C, De Rosa S, Indolfi C. J Mol Biol. 2017 Jun 16;429(12):1817-1828. doi: 10.1016/j.jmb.2017.05.008. Epub 2017 May
  10. Bioresorbable vascular scaffolds – basic concepts and clinical outcome. Indolfi C, De Rosa S, Colombo A. Nat Rev Cardiol. 2016 Dec;13(12):719-729. doi: 10.1038/nrcardio.2016.151. Epub 2016 Sep 29.
  11.  Combined optical coherence tomography morphologic and fractional flow reserve hemodynamic assessment of non- culprit lesions to better predict adverse event outcomes in diabetes mellitus patients: COMBINE (OCT-FFR) prospective study. Rationale and design. Kennedy MW, Fabris E, Ijsselmuiden AJ, Nef H, Reith S, Escaned J, Alfonso F, van Royen N, Wojakowski W, Witkowski A, Indolfi C, Ottervanger JP, Suryapranata H, Kedhi E. Cardiovasc Diabetol. 2016 Oct 10;15(1):144.
  12. Modulation of Circulating MicroRNAs Levels during the Switch from Clopidogrel to Ticagrelor. Carino A, De Rosa S, Sorrentino S, Polimeni A, Sabatino J, Caiazzo G, Torella D, Spaccarotella C, Mongiardo A, Strangio A, Filippis C, Indolfi C. Biomed Res Int. 2016;2016:3968206. doi: 10.1155/2016/3968206. Epub 2016 Jun 6. PMID: 27366745 Free PMC Article .
  13. MicroRNAs for Restenosis and Thrombosis After Vascular Injury. Gareri C, De Rosa S, Indolfi C. Circ Res. 2016 Apr 1;118(7):1170-84. doi: 10.1161/CIRCRESAHA.115.308237. Review.
  14. Exosomal miRNAs in Heart Disease. Iaconetti C, Sorrentino S, De Rosa S, Indolfi C. Physiology (Bethesda). 2016 Jan;31(1):16-24. doi: 10.1152/physiol.00029.2015. Review.
  15. The duration of balloon inflation affects the luminal diameter of coronary segments after bioresorbable vascular scaffolds deployment. Sorrentino S, De Rosa S, Ambrosio G, Mongiardo A, Spaccarotella C, Polimeni A, Sabatino J, Torella D, Caiazzo G, Indolfi C. BMC Cardiovasc Disord. 2015 Dec 11;15:169. doi: 10.1186/s12872-015-0163-5.
  16. Circulating microRNAs as Biomarkers in Cardiovascular Diseases. De Rosa S, Indolfi C. Exp Suppl. 2015;106:139-149. doi: 10.1007/978-3-0348-0955-9_6.
  17. Down-regulation of miR-23b induces phenotypic switching of vascular smooth muscle cells in vitro and in vivo. Iaconetti C, De Rosa S, Polimeni A, Sorrentino S, Gareri C, Carino A, Sabatino J, Colangelo M, Curcio A, Indolfi C. Cardiovasc Res. 2015 Sep 1;107(4):522-33. doi: 10.1093/cvr/cvv141. Epub 2015 May 20.
  18. Neointimal proliferation is associated with clinical restenosis 2 years after fully bioresorbable vascular scaffold implantation. Indolfi C, Mongiardo A, Spaccarotella C, Caiazzo G, Torella D, De Rosa S. Circ Cardiovasc Imaging. 2014 Jul;7(4):755-7. doi: 10.1161/CIRCIMAGING.114.001727.
  19. Emerging role of microRNAs in cardiovascular diseases. De Rosa S, Curcio A, Indolfi C. Circ J. 2014;78(3):567-75. Epub 2014 Feb 13. Review. PMID: 24521764 Free Article
  20. Non-coding RNAs: the “dark matter” of cardiovascular pathophysiology. Iaconetti C, Gareri C, Polimeni A, Indolfi C. Int J Mol Sci. 2013 Oct 9;14(10):19987-20018. doi: 10.3390/ijms141019987. Review. PMID: 24113581
  21. MicroRNA-1 downregulation increases connexin 43 displacement and induces ventricular tachyarrhythmias in rodent hypertrophic hearts. Curcio A, Torella D, Iaconetti C, Pasceri E, Sabatino J, Sorrentino S, Giampà S, Micieli M, Polimeni A, Henning BJ, Leone A, Catalucci D, Ellison GM, Condorelli G, Indolfi C. PLoS One. 2013 Jul 26;8(7):e70158. doi: 10.1371/journal.pone.0070158. Print 2013.
  22.  Vascular miRNAs after balloon angioplasty. Polimeni A, De Rosa S, Indolfi C. Trends Cardiovasc Med. 2013 Jan;23(1):9-14. doi: 10.1016/j.tcm.2012.08.004. Review. PMID: 23312133
  23. Inhibition of miR-92a increases endothelial proliferation and migration in vitro as well as reduces neointimal proliferation in vivo after vascular injury. Iaconetti C, Polimeni A, Sorrentino S, Sabatino J, Pironti G, Esposito G, Curcio A, Indolfi C. Basic Res Cardiol. 2012 Sep;107(5):296. doi: 10.1007/s00395-012-0296-y. Epub 2012 Aug 14.
  24. MicroRNA-133 controls vascular smooth muscle cell phenotypic switch in vitro and vascular remodeling in vivo. Torella D, Iaconetti C, Catalucci D, Ellison GM, Leone A, Waring CD, Bochicchio A, Vicinanza C, Aquila I, Curcio A, Condorelli G, Indolfi C. Circ Res. 2011 Sep 30;109(8):880-93. doi: 10.1161/CIRCRESAHA.111.240150. Epub 2011 Aug 18.
  25. Mechanisms of smooth muscle cell proliferation and endothelial regeneration after vascular injury and stenting: approach to therapy. Curcio A, Torella D, Indolfi C. Circ J. 2011;75(6):1287-96. Epub 2011 Apr 29. Review. PMID: 21532177 Free Article
  26. Differential regulation of vascular smooth muscle and endothelial cell proliferation in vitro and in vivo by cAMP/PKA-activated p85alphaPI3K. Torella D, Gasparri C, Ellison GM, Curcio A, Leone A, Vicinanza C, Galuppo V, Mendicino I, Sacco W, Aquila I, Surace FC, Luposella M, Stillo G, Agosti V, Cosentino C, Avvedimento EV, Indolfi C. Am J Physiol Heart Circ Physiol. 2009 Dec;297(6):H2015-25. doi: 10.1152/ajpheart.00738.2009. Epub 2009 Sep 25.
  27. The margination propensity of spherical particles for vascular targeting in the microcirculation. Gentile F, Curcio A, Indolfi C, Ferrari M, Decuzzi P. J Nanobiotechnology. 2008 Aug 15;6:9. doi: 10.1186/1477-3155-6-9.
  28. Fludarabine prevents smooth muscle proliferation in vitro and neointimal hyperplasia in vivo through specific inhibition of STAT-1 activation. Torella D, Curcio A, Gasparri C, Galuppo V, De Serio D, Surace FC, Cavaliere AL, Leone A, Coppola C, Ellison GM, Indolfi C. Am J Physiol Heart Circ Physiol. 2007 Jun;292(6):H2935-43. Epub 2007 Feb 9.
  29. Polytetrafluoroethylene stent deployment for a left anterior descending coronary aneurysm complicated by late acute anterior myocardial infarction.Indolfi C, Achille F, Tagliamonte G, Spaccarotella C, Mongiardo A, Ferraro A. Circulation. 2005 Aug 2;112(5):e70-1. No abstract available.
  30. The present and future of drug-eluting stents. Indolfi C, Mongiardo A, Spaccarotella C, Ferraro A, Torella D. Ital Heart J. 2005 Jun;6(6):498-506. Review.
  31. Drug-eluting stents versus bare metal stents in percutaneous coronary interventions (a meta-analysis).Indolfi C, Pavia M, Angelillo IF.Am J Cardiol. 2005 May 15;95(10):1146-52.
  32. Sirolimus-eluting vs uncoated stents for prevention of restenosis in small coronary arteries: a randomized trial. Ardissino D, Cavallini C, Bramucci E, Indolfi C, Marzocchi A, Manari A, Angeloni G, Carosio G, Bonizzoni E, Colusso S, Repetto M, Merlini PA; SES-SMART Investigators. JAMA. 2004 Dec 8;292(22):2727-34.
  33. mechanisms of restenosis after percutaneous peripheral angioplasty and approach to endovascular therapy.Mongiardo A, Curcio A, Spaccarotella C, Parise S, Indolfi C.Curr Drug Targets Cardiovasc Haematol Disord. 2004 Sep;4(3):275-87. Review.
  34. [Italian Consensus Conference on drug-eluting stents].Indolfi C, Berardi F, Bolognese L, Danzi GB, Galassi AR, Della Grazia E, Montinaro A, Paloscia L, Vassanelli C, Bartorelli A, Klugmann S, Petronio AS, Scherillo M, Marzilli M; Società Italiana di Cardiologia Invasiva. Ital Heart J Suppl. 2004 Jan;5(1):64-70. Review. Italian. No abstract available.
  35. Effect of stent coating alone on in vitro vascular smooth muscle cell proliferation and apoptosis. Curcio A, Torella D, Cuda G, Coppola C, Faniello MC, Achille F, Russo VG, Chiariello M, Indolfi C.Am J Physiol Heart Circ Physiol. 2004 Mar;286(3):H902-8. Epub 2003 Oct 30.
  36. Molecular mechanisms of in-stent restenosis and approach to therapy with eluting stents.Indolfi C, Mongiardo A, Curcio A, Torella D.Trends Cardiovasc Med. 2003 May;13(4):142-8.

Aree di ricerca:

  • Ematopoiesi clonale nell’infarto miocardico
  • Plasma Medicine: “A novel plasma medicine tool for accelerated haemostasis”: Il progetto triennale cofinanziato dalla “Fondazione con Il Sud” si propone  di sviluppare un dispositivo biomedico che sfrutti la tecnologia della  medicina al plasma per indurre localmente una rapida coagulazione sanguigna.  La medicina al plasma è una branca emergente della fisica dei plasmi e  compendia al suo interno competenze che vanno dall’ingegneria alla biologia.  Lo sviluppo di tale dispositivo permetterà di curare patologie quali  l’ematoma di tasca in pazienti che seguono terapia anticoagulante o le ulcere croniche in pazienti diabetici, senza interagire con altre terapie farmacologiche e senza indurre effetti collaterali.  Il progetto è ospitato dal Dipartimento di Scienze Mediche e Chirurgiche dell’Unversità di Catanzaro e vede la collaborazione di due importanti partner: il Consorzio RFX di Padova e il laboratorio AIST di Tsukuba (Giappone).
  • Genetica ed epigenetica degli indigeni dell’Amazzonia
  • Fisiologia Coronarica e Sistemi di Valutazione di guide di pressione. 
  • Misurazione del Cardiac Work nei pazienti sottoposti a Tavi
  • Robotica per l’interventistica coronarica (in Collaborazione con il Prof. Guido Danieli)